Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant Enterococcus faecium causing liver abscesses

J Antimicrob Chemother. 2024 Mar 1;79(3):689-691. doi: 10.1093/jac/dkad410.

Authors

Affiliations

¹ Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
² Nephrology Unit, Padua University Hospital, Padua, Italy.
³ Microbiology and Virology Unit, Padua University Hospital, Padua, Italy.
⁴ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁵ Hospital Pharmacy Unit, Padua University Hospital, Padua, Italy.

PMID: 38225167
DOI: 10.1093/jac/dkad410

No abstract available

MeSH terms

Enterococcus faecium* / genetics
Linezolid / pharmacology
Linezolid / therapeutic use
Lipoglycopeptides*
Off-Label Use
Treatment Outcome
Vancomycin* / analogs & derivatives*

Substances

oritavancin
Vancomycin
Linezolid
Lipoglycopeptides